• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association of Glucagon ‐like Peptide‐1 Receptor Agonist (GLP‐1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System
ConclusionsGLP‐1 RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - April 13, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

Association of glucagon ‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Conclusions GLP‐1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - July 5, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in...
Source: Diabetologia - August 2, 2017 Category: Endocrinology Source Type: research

Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users
ConclusionsThis study provides evidence of increased CVD risk associated with hypoglycaemia, especially serious hypoglycaemia events. While associations were attenuated with non‐serious hypoglycaemia, the results were suggestive of a potential increased risk.
Source: Diabetes, Obesity and Metabolism - May 1, 2017 Category: Endocrinology Authors: Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty, David D. Dore Tags: ORIGINAL ARTICLE Source Type: research

Deep learning approach for diabetes prediction using PIMA Indian dataset
ConclusionThe outcome of the study confirms that DL provides the best results with the most promising extracted features. DL achieves the accuracy of 98.07% which can be used for further development of the automatic prognosis tool. The accuracy of the DL approach can further be enhanced by including the omics data for prediction of the onset of the disease.
Source: Journal of Diabetes and Metabolic Disorders - April 13, 2020 Category: Endocrinology Source Type: research

Electronic Medical Record Risk Modeling of Cardiovascular Outcomes Among Patients with Type 2 Diabetes
ConclusionsThe Ochsner model overestimated 5-year CHD risk, but had relatively higher calibration than the other models in CHD. Risk equations fitted for local populations improved cardiovascular risk stratification for patients with T2DM. Application of machine learning simplified the models compared to “generalized” risk equations.
Source: Diabetes Therapy - June 18, 2021 Category: Endocrinology Source Type: research

Impact of Visit-to-Visit Triglyceride-Glucose Index Variability on the Risk of Cardiovascular Disease in the Elderly
CONCLUSIONS: High variability in TyG was significantly associated with elevated CVD risk in the elderly, independent of average TyG and other risk factors. Close monitoring variability in TyG might be informative to identify old individuals at high risk of CVD.PMID:36159087 | PMC:PMC9507760 | DOI:10.1155/2022/5125884
Source: International Journal of Endocrinology - September 26, 2022 Category: Endocrinology Authors: Fei Chen Ying Pan Ziqing Liu Rong Huang Jing Wang Jian Shao Yaqin Gong Xiyi Sun Xiaobo Jiang Weihao Wang Zhaoqiang Li Shao Zhong Qi Pan Kaixin Zhou Source Type: research